^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BMS-986310
i
Other names: BMS-986310, ONO-4578, ONO 4578, BMS986310, BMS 986310, ONO4578
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BMS, Ono Pharma
Drug class:
PGE4 antagonist
Related drugs:
5ms
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer (clinicaltrials.gov)
P1, N=46, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Trial completion date: Jul 2025 --> Apr 2026 | Trial primary completion date: Jul 2025 --> Apr 2026
Trial completion date • Trial primary completion date
|
Ibrance (palbociclib) • Verzenio (abemaciclib) • letrozole • BMS-986310
6ms
Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=183, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Trial completion date: Jan 2026 --> Mar 2027 | Trial primary completion date: Jan 2026 --> Mar 2027
Trial completion date • Trial primary completion date
|
Opdivo (nivolumab) • BMS-986310
7ms
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer (clinicaltrials.gov)
P2, N=144, Not yet recruiting, Ono Pharmaceutical Co. Ltd
New P2 trial
|
Opdivo (nivolumab) • Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • BMS-986310
10ms
ONO-4578-04: An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov)
P1, N=46, Completed, Ono Pharmaceutical Co. Ltd | Active, not recruiting --> Completed
Trial completion
|
Opdivo (nivolumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • BMS-986310 • levoleucovorin calcium
1year
ONO-4578-04: An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov)
P1, N=46, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Trial completion date: Nov 2024 --> Mar 2025
Trial completion date • Combination therapy • Metastases
|
Opdivo (nivolumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • BMS-986310 • levoleucovorin calcium
over1year
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer (clinicaltrials.gov)
P1, N=46, Active, not recruiting, Ono Pharmaceutical Co. Ltd
New P1 trial • Metastases
|
Ibrance (palbociclib) • Verzenio (abemaciclib) • letrozole • BMS-986310
over1year
Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=183, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Trial completion date: Sep 2025 --> Jan 2026 | Trial primary completion date: Sep 2025 --> Jan 2026
Trial completion date • Trial primary completion date • Metastases
|
Opdivo (nivolumab) • BMS-986310
over1year
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer (clinicaltrials.gov)
P1, N=40, Active, not recruiting, Ono Pharmaceutical Co. Ltd
New P1 trial • Combination therapy • Metastases
|
Opdivo (nivolumab) • Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • BMS-986310 • levoleucovorin calcium
over1year
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov)
P1, N=42, Active, not recruiting, Ono Pharmaceutical Co. Ltd
New P1 trial • Combination therapy • Metastases
|
Opdivo (nivolumab) • docetaxel • Cyramza (ramucirumab) • BMS-986310
over1year
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov)
P1, N=46, Active, not recruiting, Ono Pharmaceutical Co. Ltd
New P1 trial • Combination therapy • Metastases
|
Opdivo (nivolumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • BMS-986310 • levoleucovorin calcium
over1year
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) (clinicaltrials.gov)
P2, N=210, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Recruiting --> Active, not recruiting | Trial completion date: Dec 2027 --> Jul 2027
Enrollment closed • Trial completion date • Combination therapy • Metastases
|
Opdivo (nivolumab) • capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • BMS-986310
almost2years
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) (clinicaltrials.gov)
P2, N=210, Recruiting, Ono Pharmaceutical Co. Ltd
New P2 trial • Combination therapy • Metastases
|
Opdivo (nivolumab) • capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • BMS-986310
Share via
